516 patents
Page 8 of 26
Utility
Imidazole and Triazole Kras Inhibitors
29 Sep 22
Chao Qi, Xiaozhao Wang, Wenqing Yao
Filed: 22 Mar 22
Utility
Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
27 Sep 22
The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan
Filed: 8 Sep 20
Utility
Tricyclic amine compounds as CDK2 inhibitors
20 Sep 22
Qinda Ye, Ken Mukai, Liangxing Wu, Wenqing Yao
Filed: 30 Apr 20
Utility
Salts of the Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-YL)-1h-Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile
15 Sep 22
The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Hui-Yin Li, James D. Rodgers
Filed: 29 Nov 21
Utility
Tricyclic amine compounds as CDK2 inhibitors
13 Sep 22
The present application provides tricyclic amine compounds, which are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Qinda Ye, Neil Lajkiewicz, Ken Mukai, Liangxing Wu, Wenqing Yao
Filed: 30 Apr 20
Utility
Ruxolitinib Formulation for Reduction of Itch In Atopic Dermatitis
8 Sep 22
This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.
Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, Jim Lee
Filed: 28 Mar 22
Utility
Spirocyclic Lactams As JAK2 V617F Inhibitors
8 Sep 22
The present application provides spirocyclic lactam compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Stacey Shepard, Charles Cole, Nikoo Falahatpisheh, Kai Liu, Lixin Shao, Darius Vrubliauskas, Liangxing Wu, Wenqing Yao, Eddy W. Yue
Filed: 24 Feb 22
Utility
Heterocyclylamines as PI3K inhibitors
6 Sep 22
Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks, Brent Douty, Chunhong He
Filed: 24 Mar 20
Utility
Formulations of an Axl/mer Inhibitor
1 Sep 22
The present application relates to pharmaceutical formulations and dosage forms of an AXL/MER inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of AXL/MER mediated diseases such as cancer.
William L. Rocco, Francis X. Muller
Filed: 28 Dec 21
Utility
Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
30 Aug 22
The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Qinda Ye, Jingwei Li, Ken Mukai, Brandon Smith, Liangxing Wu, Wenqing Yao, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
Filed: 13 Aug 20
Utility
Imidazopyridazine and imidazopyridine compounds and uses thereof
30 Aug 22
Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
Filed: 19 Dec 19
Utility
Heteroaryl amide compounds as sting activators
30 Aug 22
The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
Filed: 23 Oct 20
Utility
Heterocyclic compounds as immunomodulators
16 Aug 22
Liangxing Wu, Kaijiong Xiao, Wenqing Yao
Filed: 29 Dec 20
Utility
HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
11 Aug 22
Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue, Artem Shvartsbart, David M. Burns, Daniel Levy
Filed: 23 Feb 21
Utility
Pyrazolopyridine compounds and uses thereof
9 Aug 22
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Alexander Sokolsky, Oleg Vechorkin, Kai Liu, Jun Pan, Wenqing Yao, Qinda Ye
Filed: 22 Jul 19
Utility
JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
9 Aug 22
This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating chronic lung allograft dysfunction such as, e.g., bronchiolitis obliterans syndrome.
Richard L. Schaub, Kevin O'Hayer
Filed: 5 Mar 20
Utility
Heterocyclic compounds as immunomodulators
9 Aug 22
Liangxing Wu, Bo Shen, Jingwei Li, Zhenwu Li, Kai Liu, Fenglei Zhang, Wenqing Yao
Filed: 11 Dec 20
Utility
Derivatives of an FGFR inhibitor
9 Aug 22
The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.
Ming Tao, Jason Boer
Filed: 3 Dec 20
Utility
Treatment of Hidradenitis Suppurativa Using Jak Inhibitors
4 Aug 22
The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.
Michael D. Howell, Paul Smith
Filed: 13 Apr 22
Utility
Combination Therapy with an ANTI-CD19 Antibody and Parsaclisib
4 Aug 22
The present disclosure describes a combination of an anti-CD19 antibody and parsaclisib for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.
Peter Langmuir
Filed: 30 Nov 21